These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21306252)

  • 1. Everolimus and giant-cell astrocytomas in tuberous sclerosis.
    Jia J; Xiong L; Chen S
    N Engl J Med; 2011 Feb; 364(6):577. PubMed ID: 21306252
    [No Abstract]   [Full Text] [Related]  

  • 2. Everolimus and giant-cell astrocytomas in tuberous sclerosis.
    Nawashiro H; Shinomiya N
    N Engl J Med; 2011 Feb; 364(6):576-7; author reply 577. PubMed ID: 21306253
    [No Abstract]   [Full Text] [Related]  

  • 3. mTOR inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis.
    Komotar RJ; Starke RM; Connolly ES; Sisti MB
    Neurosurgery; 2011 Apr; 68(4):N24-5. PubMed ID: 21792104
    [No Abstract]   [Full Text] [Related]  

  • 4. Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Józwiak S; Stein K; Kotulska K
    Future Oncol; 2012 Dec; 8(12):1515-23. PubMed ID: 23231513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
    Krueger DA; Care MM; Holland K; Agricola K; Tudor C; Mangeshkar P; Wilson KA; Byars A; Sahmoud T; Franz DN
    N Engl J Med; 2010 Nov; 363(19):1801-11. PubMed ID: 21047224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
    Mateos-González ME; López-Laso E; Vicente-Rueda J; Camino-León R; Fernández-Ramos JA; Baena-Gómez MA; Peña-Rosa MJ
    Rev Neurol; 2014 Dec; 59(11):497-502. PubMed ID: 25418144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus tablets for patients with subependymal giant cell astrocytoma.
    Turner SG; Peters KB; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
    Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex.
    Jiang T; Du J; Raynald ; Wang J; Li C
    World Neurosurg; 2017 Nov; 107():1053.e1-1053.e6. PubMed ID: 28866062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Major P
    Aging (Albany NY); 2011 Mar; 3(3):189-91. PubMed ID: 21415462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
    Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent communicating hydrocephalus in adult tuberous sclerosis patients: a possible therapeutic role for everolimus.
    Laviv Y; Jackson S; Rappaport ZH
    Acta Neurochir (Wien); 2015 Feb; 157(2):241-5. PubMed ID: 25524658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
    Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of subependymal giant cell astrocytoma with spinal cord metastasis to everolimus.
    Aguilera D; Flamini R; Mazewski C; Schniederjan M; Hayes L; Boydston W; Castellino RC; MacDonald TJ
    J Pediatr Hematol Oncol; 2014 Oct; 36(7):e448-51. PubMed ID: 24276039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex.
    Appalla D; Depalma A; Calderwood S
    Pediatr Blood Cancer; 2016 Jul; 63(7):1276-8. PubMed ID: 26929034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex.
    Fukumura S; Watanabe T; Takayama R; Minagawa K; Tsutsumi H
    J Child Neurol; 2015 Aug; 30(9):1192-5. PubMed ID: 25143481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic update in tuberous sclerosis complex: the role of mTOR pathway inhibitors].
    Ruiz-Falcó Rojas ML
    Rev Neurol; 2012 May; 54 Suppl 3():S19-24. PubMed ID: 22605628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
    Trelinska J; Dachowska I; Kotulska K; Baranska D; Fendler W; Jozwiak S; Mlynarski W
    Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
    Ebrahimi-Fakhari D; Franz DN
    Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
    Franz DN
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.